Belgian Celyad granted an exclusive license to Osaka based ONO Pharmaceutical for the development and commercialisation of Celyad’s unique allogeneic cell therapy in Japan, Korea and Taiwan.

Celyad biotech cancer ono car-t nkThis license agreement opens new markets to Celyad and its NKR-2 T-cell cancer immunotherapy. In addition to a deal worth up to €282M, Celyad will also receive double digit royalties based on net sales of the licensed product in Japan-based ONO’s territories.

Celyad’s Natural Killer Receptor (NKR) based T-Cell platform targets a wide range of solid and hematological tumors, and is currently in Phase I trials for acute myeloid leukemia and multiple myeloma patients.

ADVERTISEMENT

Unlike traditional CAR-T cell therapy, which target only one tumor antigen, NK cell receptors enable a single receptor to recognise multiple tumor antigens. The trial is designed to assess the safety and feasibility of NKR-2, with secondary endpoints including clinical activity.

NK Killer cells Celyad ONO Biotech Therapy

The major benefit of using those NK cells receptors in cancer treatment is that they have the potential to target a broad range of cancers such as lymphoma, colorectal, ovarian cancer and myeloma. (Source: Celyad)

Additional benefits of this approach include the fact that the NKR-2 program does not employ patient pre-conditioning of the immune system, thereby avoiding the toxicities associated with chemotherapy and allowing the immune system to remain intact.

Celyad’s allogeneic platform engineers the T-Cells of healthy donors, that also express TCR Inhibitory Molecules (TIMs), to avoid having the engineered donor cells be rejected by the patient’s normal tissues.

There are significant cost-related benefits to an allogenic platform too, which is the basis for an ‘off-the shelf‘ therapy. As multiple treatments are be made from a single donor, the cost of each dose is lowered.

Celyad CAR-T Cancer Cell Therapy ONO

For allogenic NKR-2, Celyad collects the patient’s own T-Cells and engineers them to express NKG2D in order to target cancer cells effectively. (Source: Celyad)

And whilst this Belgian biotech has had a disappointing quarter for its Cardiology program (as did a few biotechs), its CAR-T work has instead seen encouraging progress. Celyad also holds key patents in the CAR-T field, which was also one of the main reasons why it successfully IPOed on the NASDAQ and raised over $100M.

This is a difficult period for CAR-T, the field of which has faced a lot of hype and then just some last week received some upsetting news in the US.

However, this partnership is the next solid step for other CAR-T biotechs to ‘get back on the horse’, so to speak. 


George Rawadi spoke to Labiotech at our conference Refresh in May…


Feature Image Credit: Celyad

Previous post

How did Helen Lee overcome barriers to HIV Diagnostics in the 'Real World'?

Next post

We are now Media Partners of BioFIT 2016!

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.